SaiAo Biotech is a biotechnology company dedicated to the research, development, and clinical application of CAR-T cell therapy. Through strategic partnership with Nanfang-Chunfu Children's Institute of Hematology & Oncology, a leading institution under GoBroad Healthcare Group, we provide world-class cell therapy treatments to patients worldwide.
Founded with a vision to make advanced cell therapy accessible and affordable, we have established a complete industrial chain spanning from cell collection, manufacturing, quality control to clinical application. Our partnership ensures that patients receive the highest standard of care backed by extensive clinical experience and cutting-edge research
Nanfang‑Chunfu Institute of Hematology & Oncology is a premier hematology research and treatment center under GoBroad Healthcare Group. Located in Dongguan, China, the institute is dedicated to advancing the diagnosis and treatment of blood diseases, with particular expertise in CAR‑T cell therapy and HSCT.
The institute combines cutting‑edge research with compassionate patient care, making it one of China's leading centers for hematological malignancy treatment. Its collaboration with SaiAo and Yake Biotech brings together clinical excellence with advanced cell therapy manufacturing capabilities.
Founded by renowned hematology expert Prof. Chunfu Li with decades of clinical and research experience
Specializes in comprehensive treatment of hematological malignancies including leukemia, thalassaemia, lymphoma, and multiple myeloma
One of China's leading centers for CAR‑T clinical research with thousands of treated cases
Active participant in international multicenter clinical trials and collaborative research
Published extensively in top‑tier international journals including Blood, Lancet Hematology, and Journal of Clinical Oncology
To date, more than 1400 transplant cases have been performed
More than 430 cases received TCRab T‑cell depleted transplant
884 Thal‑HCTs have achieved a 4‑year survival rate of 97.6%
Matched sibling donor HCT for TM Twins in 2022
Published 100+ peer‑reviewed papers in top‑tier international hematology journals
Developed optimized CAR‑T treatment protocols that have been adopted by institutions worldwide
Contributed to the development of China's industry standards for CAR‑T therapy
Regular presenter at major international conferences including ASH, EHA, and EBMT
Dr. Alex H. Chang is an Adjunct Professor at the School of Life Sciences, Fudan University, He earned his Ph.D. from the University of British Columbia, Canada, and subsequently completed postdoctoral training at Weill Medical College of Cornell University. He later served as a senior scientist at Memorial SloanKettering Cancer Center, during which time he published several papers on cell engineering and gene therapy in leading journals, including Nature Biotechnology, Nature Medicine, and Molecular Therapy.
Dr. Alex H. Chang
Prof. Chunfu Li，Head of Nanfang-Chunfu Children’s Institute of Hematology & Oncology，Founder and Honorary President of Thalassaemia Association of Guangdong Province，Training after master，St. Jude Children's Research Hospital and MD Anderson Cancer Center, USA in 1999，Pesaro BMT Center, Italy, in 2000，Achievement，Acquired "Soong Ching Ling Award in Pediatrics " in 2017，Served as pediatrics for more than 40 years. And finished >1400 transplant cases，Published many papers in “Blood”, “BJH”, “AJH”, “Blood Adv.”, and ”.J. A. C. Immunology”.
Prof. Chunfu Li
Dr. Yuelin He，Vice Headt of Nanfang-Chunfu Children’s Institute of Hematology & Oncology，Vice director Thalassaemia Association of Guangdong Province
Training ，HongKong University；Served as pediatrics for more than 30 years. And finished >1200 transplant cases。Published many papers in “Blood”, “BJH”, “AJH”, and “Blood Advance”.
Dr. Yuelin He
Huaying Liu，Associate chief physician ，Focus on diagnosis and treatment of lymphoblastic leukemia (ALL) in children，CarT cell immunotherapy and hematopoietic stem cell transplantation. She studied at City of Hope Medical Center and Mayo Clinic in the United States
Huaying Liu
Lan He，Associate chief physician，Hematopoietic stem cell transplantation for aplastic anemia (AA) and autoimmune diseases, diagnosis and treatment of acute and critical diseases in children
Lan He
Ye Zhizhong Professor，Former President of Shenzhen Rheumatism Specialist Hospital (Former Director of Shenzhen Rheumatism Specialty Hospital)，Director of the Institute of Rheumatology, Guangdong Medical College Adjunct Professor at Shenzhen University，Vice Chairman of the Rheumatology Professional Committee, China Association of Integrative Medicine，Chairman of the Rheumatology Professional Committee, Shenzhen Medical Association。
Ye Zhizhong Professor
